Precision Multiplex Monitoring of Fibrosis Biomarkers in Chronic Kidney Disease – Tracking Disease Progression and Therapeutic Response
Chronic Kidney Disease (CKD) affects millions worldwide and is a leading cause of morbidity and mortality. Early detection of fibrotic processes is crucial for developing therapeutic strategies to mitigate the loss of kidney function
FibroKey™ is a multiplexed MS-based assay delivering a robust solution for monitoring fibrosis mechanisms through the quantification of over 35 validated biomarkers in urine. This assay leverages mass spectrometry to provide detailed insights into the fibrotic processes involved in CKD, supporting both clinical and therapeutic research.
FibroKey™ features a robust panel of 35+ fibrosis-related biomarkers, providing a thorough overview of the extracellular matrix (ECM) remodeling and inflammatory processes central to chronic kidney disease (CKD). Among the dozens of markers included, key highlights include:
Each marker is carefully validated through the InoKey™ workflow, ensuring precision and reproducibility. This comprehensive biomarker panel enables precise monitoring and tracking of therapeutic efficacy, supporting research into various stages of CKD and other fibrotic diseases.
Read our case study and learn more about 35+ biomarkers selected and validated for FibroKey™
FibroKey™ enables precise disease monitoring with mass spectrometry-based quantification of fibrosis biomarkers. Its multiplex design reduces the need for multiple tests, offering a more efficient approach to understanding fibrosis pathways.
Researchers can gain real-time insights into disease progression and therapeutic efficacy through FibroKey’s ability to monitor fibrosis through urine samples, providing an alternative to traditional invasive procedures.
FibroKey™ leverages the power of mass spectrometry to detect biomarkers at low concentrations, offering high sensitivity and specificity across fibrosis-related pathways. This ensures that even subtle changes in disease progression are accurately captured, providing reliable data for drug development and clinical studies.
Measure proteins which pharmaceutical companies care about at the precision needed to enable decision-making and FDA submissions in three easy steps
After designing your custom experimental assay with our with our proteomics experts, send your non-invasive urine samples to our CLIA, FDA-inspected (US), or GCP/GLP (UK) certified labs.
FibroKey™ utilizes mass spectrometry to quantify proteins involved in fibrosis—detailed analysis of fibrosis markers, providing insights into disease progression and treatment efficacy.
The assay supports therapeutic evaluation by offering extended validation for exploratory and secondary endpoints. This ensures reliable data for clinical trials or LDTs, enabling precise monitoring of therapeutic impact and disease progression.
Don’t miss out on this limited-time opportunity to gain a competitive edge and achieve groundbreaking discoveries. Please fill out this form to access the MasterKey™ catalog.
Please fill out this form to access the MasterKey™ catalog and to stay updated with newly added proteins
Please fill out the form to subscribe to our newsletter.